Matthew Biegler
Stock Analyst at Oppenheimer
(4.02)
# 608
Out of 5,112 analysts
87
Total ratings
39.74%
Success rate
18.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OLMA Olema Pharmaceuticals | Maintains: Outperform | $45 → $48 | $30.81 | +55.79% | 9 | Dec 11, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Outperform | $45 | $28.61 | +57.27% | 1 | Dec 4, 2025 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $12 → $15 | $8.09 | +85.53% | 6 | Nov 14, 2025 | |
| BBOT BridgeBio Oncology Therapeutics | Maintains: Outperform | $23 → $22 | $12.06 | +82.50% | 2 | Nov 13, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Outperform | $30 → $28 | $18.01 | +55.47% | 3 | Oct 10, 2025 | |
| ACRV Acrivon Therapeutics | Maintains: Outperform | $9 → $8 | $2.26 | +253.98% | 4 | Aug 14, 2025 | |
| CTMX CytomX Therapeutics | Initiates: Outperform | $7 | $3.88 | +80.41% | 1 | Jul 31, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Outperform | $10 → $9 | $1.42 | +533.80% | 2 | May 14, 2025 | |
| VOR Vor Biopharma | Reiterates: Outperform | $160 | $12.80 | +1,150.00% | 7 | Mar 21, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $40 → $45 | $11.28 | +298.94% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $105 → $115 | $121.47 | -5.33% | 1 | Dec 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $53 | $33.26 | +59.35% | 5 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $33 | $22.99 | +43.54% | 6 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $1.42 | +1,308.45% | 7 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $8.13 | - | 6 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $7.36 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $12.16 | +15.13% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $7.99 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.05 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $9.97 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.76 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.25 | - | 2 | Dec 22, 2022 |
Olema Pharmaceuticals
Dec 11, 2025
Maintains: Outperform
Price Target: $45 → $48
Current: $30.81
Upside: +55.79%
Ascentage Pharma Group International
Dec 4, 2025
Initiates: Outperform
Price Target: $45
Current: $28.61
Upside: +57.27%
ORIC Pharmaceuticals
Nov 14, 2025
Maintains: Outperform
Price Target: $12 → $15
Current: $8.09
Upside: +85.53%
BridgeBio Oncology Therapeutics
Nov 13, 2025
Maintains: Outperform
Price Target: $23 → $22
Current: $12.06
Upside: +82.50%
Nurix Therapeutics
Oct 10, 2025
Maintains: Outperform
Price Target: $30 → $28
Current: $18.01
Upside: +55.47%
Acrivon Therapeutics
Aug 14, 2025
Maintains: Outperform
Price Target: $9 → $8
Current: $2.26
Upside: +253.98%
CytomX Therapeutics
Jul 31, 2025
Initiates: Outperform
Price Target: $7
Current: $3.88
Upside: +80.41%
Allogene Therapeutics
May 14, 2025
Maintains: Outperform
Price Target: $10 → $9
Current: $1.42
Upside: +533.80%
Vor Biopharma
Mar 21, 2025
Reiterates: Outperform
Price Target: $160
Current: $12.80
Upside: +1,150.00%
Arvinas
Feb 12, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $11.28
Upside: +298.94%
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $121.47
Upside: -5.33%
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $33.26
Upside: +59.35%
Sep 19, 2024
Maintains: Outperform
Price Target: $25 → $33
Current: $22.99
Upside: +43.54%
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $1.42
Upside: +1,308.45%
Sep 10, 2024
Downgrades: Perform
Price Target: n/a
Current: $8.13
Upside: -
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $7.36
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $12.16
Upside: +15.13%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $7.99
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.05
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $9.97
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.76
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.25
Upside: -